Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 14/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 9/20 | 0.64 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.64 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.64 |
| ▸ | CYP2C9 | P11712 | 6/20 | 0.60 |
| ▸ | LMNA | P02545 | 4/20 | 0.58 |
| ▸ | HPGD | P15428 | 2/20 | 0.58 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.58 |
| ▸ | CTSB | P07858 | 1/20 | 0.57 |
| ▸ | CYP2C19 | P33261 | 5/20 | 0.55 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.55 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.55 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.55 |
| ▸ | MEN1 | O00255 | 2/20 | 0.54 |
| ▸ | PKM | P14618 | 1/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.53 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.53 |
| ▸ | HTT | P42858 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL259406 | 0.88 | MAPT (0.69) | MAPTALDH1A1SMN1; SMN2CYP2C9LMNA | |
| SCHEMBL8794400 | 0.86 | ALDH1A1 (0.69) | MAPTALDH1A1SMN1; SMN2NPSR1LMNA | |
| SCHEMBL25891601 | 0.84 | ALDH1A1 (0.68) | MAPTALDH1A1SMN1; SMN2NPSR1CYP2C9 | |
| SCHEMBL6125268 | 0.83 | ALDH1A1 (0.66) | MAPTALDH1A1SMN1; SMN2CYP2C9LMNA | |
| SCHEMBL5552187 | 0.82 | MAPT (0.64) | MAPTALDH1A1SMN1; SMN2LMNAL3MBTL1 | |
| SCHEMBL30699269 | 0.82 | MAPT (0.64) | MAPTALDH1A1SMN1; SMN2NPSR1CYP2C9 | |
| SCHEMBL7809569 | 0.82 | MAPT (0.64) | MAPTALDH1A1SMN1; SMN2NPSR1CYP2C9 | |
| SCHEMBL30953903 | 0.82 | MAPT (0.64) | MAPTALDH1A1SMN1; SMN2NPSR1CYP2C9 | |
| SCHEMBL5824515 | 0.82 | MAPT (0.64) | MAPTALDH1A1SMN1; SMN2NPSR1CYP2C9 | |
| SCHEMBL27038561 | 0.82 | MAPT (0.64) | MAPTALDH1A1SMN1; SMN2NPSR1CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4684837-A1 | NOVEL MODULATORS OF THE 5-HYDROXYTRYPTAMINE RECEPTOR 7 AND THEIR METHOD OF USE | Temple University of the Commonwealth System of Higher Education (US) | 2026-01-28 | — | — | EP | disclosed |
| US-20250282790-A1 | NOVEL MODULATORS OF THE 5-HYDROXYTRYPTAMINE RECEPTOR 7 AND THEIR METHOD OF USE | PRAEVENTIX, LLC | 2025-09-11 | — | — | US | disclosed |
| EP-3541790-B1 | 3-(2-(4-PHENYLPIPERAZIN-1-YL)ETHYL)-2-OXA-8-AZASPIRO[4.5]DECAN-1-ONE DERIVATIVES AND RELATED COMPOUNDS AS 5-HYDROXYTRYPTAMINE RECEPTOR 7 (5-HT7) MODULATORS FOR TREATING E.G. INFLAMMATORY BOWEL DISEASE, CIRCADIAN RHYTHM DISORDER OR DEPRESSION | UNIV TEMPLE (US) | 2025-09-03 | — | — | EP | disclosed |
| US-12338247-B2 | Modulators of the 5-hydroxytryptamine receptor 7 and their method of use | TEMPLE UNIVERSITY-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2025-06-24 | — | — | US | disclosed |
| CN-119977980-A | Novel modulators of 5-hydroxytryptamine receptor 7 and methods of use thereof | 英联邦高等教育系统坦普尔大学 | 2025-05-13 | — | — | CN | disclosed |
| CN-110177776-B | Novel modulators of 5-hydroxytryptamine receptor 7 and methods of use thereof | 英联邦高等教育系统坦普尔大学 | 2025-02-28 | — | — | CN | disclosed |
| US-11760752-B2 | Carboxylic acid, acyl sulfonamide and acyl sulfamide-derivatized bicyclic aza-heteroaromatics as selective Mcl-1 inhibitors and as dual Mcl-1/Bcl-2 inhibitors | UNIVERSITY OF MARYLAND, BALTIMORE (US) | 2023-09-19 | — | — | US | disclosed |
| US-20230112888-A1 | NOVEL MODULATORS OF THE 5-HYDROXYTRYPTAMINE RECEPTOR 7 AND THEIR METHOD OF USE | PRAEVENTIX, LLC | 2023-04-13 | — | — | US | disclosed |
| US-11319327-B2 | Modulators of the 5-hydroxytryptamine receptor 7 and their method of use | Temple University—Of the Commonwealth System of Higher Education (US) | 2022-05-03 | — | — | US | disclosed |
| US-11319327-B2 | Modulators of the 5-hydroxytryptamine receptor 7 and their method of use | Temple University—Of the Commonwealth System of Higher Education (US) | 2022-05-03 | — | — | US | disclosed |
| US-20210238189-A1 | NOVEL MODULATORS OF THE 5-HYDROXYTRYPTAMINE RECEPTOR 7 AND THEIR METHOD OF USE | PRAEVENTIX, LLC | 2021-08-05 | — | — | US | disclosed |
| US-20210238189-A1 | NOVEL MODULATORS OF THE 5-HYDROXYTRYPTAMINE RECEPTOR 7 AND THEIR METHOD OF USE | PRAEVENTIX, LLC | 2021-08-05 | — | — | US | disclosed |
| US-10858368-B2 | Modulators of the 5-hydroxytryptamine receptor 7 and their method of use | Temple University—Of the Commonwealth System of Higher Education (US) | 2020-12-08 | — | — | US | disclosed |
| US-10858368-B2 | Modulators of the 5-hydroxytryptamine receptor 7 and their method of use | Temple University—Of the Commonwealth System of Higher Education (US) | 2020-12-08 | — | — | US | disclosed |
| US-20200299285-A1 | CARBOXYLIC ACID, ACYL SULFONAMIDE AND ACYL SULFAMIDE-DERIVATIZED BICYCLIC AZA-HETEROAROMATICS AS SELECTIVE MCL-1 INHIBITORS AND AS DUAL MCL-1/BCL-2 INHIBITORS | UNIVERSITY OF MARYLAND, BALTIMORE | 2020-09-24 | — | — | US | disclosed |
| EP-3541790-A1 | NOVEL MODULATORS OF THE 5-HYDROXYTRYPTAMINE RECEPTOR 7 AND THEIR METHOD OF USE | Temple University - Of The Commonwealth System of Higher Education (US) | 2019-09-25 | — | — | EP | disclosed |
| WO-2018093818-A1 | NOVEL MODULATORS OF THE 5-HYDROXYTRYPTAMINE RECEPTOR 7 AND THEIR METHOD OF USE | TEMPLE UNIVERSITY-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2018-05-24 | — | — | WO | disclosed |
| WO-2018093818-A1 | NOVEL MODULATORS OF THE 5-HYDROXYTRYPTAMINE RECEPTOR 7 AND THEIR METHOD OF USE | TEMPLE UNIVERSITY-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2018-05-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250282790-A1 | NOVEL MODULATORS OF THE 5-HYDROXYTRYPTAMINE RECEPTOR 7 AND THEIR METHOD OF USE | HTR7, HTR5A, HTR6 | MAPT 1607/4885ALDH1A1 2885/4885SMN1; SMN2 2741/4885 |
| US-20200299285-A1 | CARBOXYLIC ACID, ACYL SULFONAMIDE AND ACYL SULFAMIDE-DERIVATIZED BICYCLIC AZA-HETEROAROMATICS AS SELECTIVE MCL-1 INHIBITORS AND AS DUAL MCL-1/BCL-2 INHIBITORS | MCL1, BCLAF1, BCL2A1 | MAPT 4738/4885ALDH1A1 353/4885SMN1; SMN2 1080/4885 |
| US-11760752-B2 | Carboxylic acid, acyl sulfonamide and acyl sulfamide-derivatized bicyclic aza-heteroaromatics as selective Mcl-1 inhibitors and as dual Mcl-1/Bcl-2 inhibitors | MCL1, BCLAF1, BCL2A1 | MAPT 4738/4885ALDH1A1 353/4885SMN1; SMN2 1080/4885 |
| US-10858368-B2 | Modulators of the 5-hydroxytryptamine receptor 7 and their method of use | HTR7, HTR6, HTR5A | MAPT 1443/4885ALDH1A1 2880/4885SMN1; SMN2 2544/4885 |
| US-20230112888-A1 | NOVEL MODULATORS OF THE 5-HYDROXYTRYPTAMINE RECEPTOR 7 AND THEIR METHOD OF USE | HTR7, HTR5A, HTR6 | MAPT 1607/4885ALDH1A1 2885/4885SMN1; SMN2 2741/4885 |
| US-11319327-B2 | Modulators of the 5-hydroxytryptamine receptor 7 and their method of use | HTR7, HTR6, HTR5A | MAPT 1443/4885ALDH1A1 2880/4885SMN1; SMN2 2544/4885 |
| US-12338247-B2 | Modulators of the 5-hydroxytryptamine receptor 7 and their method of use | HTR7, HTR6, HTR5A | MAPT 1443/4885ALDH1A1 2880/4885SMN1; SMN2 2544/4885 |
| US-20210238189-A1 | NOVEL MODULATORS OF THE 5-HYDROXYTRYPTAMINE RECEPTOR 7 AND THEIR METHOD OF USE | HTR7, HTR5A, HTR6 | MAPT 1607/4885ALDH1A1 2885/4885SMN1; SMN2 2741/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.